Thio-2 inhibits key signaling pathways required for the development and progression of castration resistant prostate cancer. (2024)
Attributed to:
BAG-1: A novel strategy for targeting the androgen receptor splice variants in castrate resistant prostate cancer.
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1158/1535-7163.mct-23-0354
PubMed Identifier: 38412481
Publication URI: http://europepmc.org/abstract/MED/38412481
Type: Journal Article/Review
Parent Publication: Molecular cancer therapeutics
ISSN: 1535-7163